Program
belzutifan
Also written as “Belzutifan” and “Belzutifan 120mg”.
Its studies are mostly in Carcinoma, Renal Cell · Neoplasms · von Hippel-Lindau Disease · Pheochromocytoma · Breast Neoplasms, led by Merck.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 2415 open or running | phase 3since Dec 10, 2019 | Aug 3, 2016 | Feb 26, 2027phase 2 · NCT03634540 |
Also a collaborator on its studies: Eisai.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Aug 3, 2016.
- Oct 9, 2020Phase 3 study in Carcinoma, Renal CellNCT04586231 · 747 enrolled · United States, Argentina, Australia and more
- Nov 10, 20202 phase 2 studies in Carcinoma, Renal CellNCT04626518, NCT04626479
- Jan 29, 2021Phase 3 study in Carcinoma, Renal CellNCT04736706 · 1,688 enrolled · United States, Australia, Brazil and more
- Apr 7, 2021Phase 1 study in Carcinoma, Renal CellNCT04846920 · 29 enrolled · United States
- Jun 8, 2021Phase 2 study in PheochromocytomaNCT04924075 · 355 planned · United States, Australia, Canada and more
- Jul 16, 2021Phase 2 study in NeoplasmsNCT04976634 · 730 enrolled · United States, Australia, Belgium and more
- Aug 2, 20213 phase 1 studiesNCT04995484, NCT04994522, NCT05030506
- Feb 4, 2022Phase 3 study in Carcinoma, Renal CellNCT05239728 · 1,800 enrolled · United States, Australia, Brazil and more
- Jun 2, 2023Phase 3 study in Carcinoma, Renal CellNCT05899049 · 251 enrolled · China
- May 20, 2024Phase 2 study in Breast NeoplasmsNCT06428396 · 120 enrolled · United States, Argentina, Canada and more
- Mar 25, 2025Phase 1 study in HealthyNCT06903715 · 14 enrolled · United States
- Aug 12, 2025Phase 1 study in HealthyNCT07121959 · 14 enrolled · United States
- Feb 5, 2026Phase 3 study in von Hippel-Lindau DiseaseNCT07405164 · 450 planned · United States, Australia, Belgium and more
- Jul 8, 2026Phase 2 study in NeoplasmsNCT07700758 · 15 planned · United States, Belgium, Denmark and more
Ahead
- Feb 26, 2027Primary completion: phase 2 study in Carcinoma, Renal CellNCT03634540
- Mar 22, 2027Primary completion: phase 2 study in NeoplasmsNCT04976634
- Apr 29, 2027Primary completion: phase 2 study in von Hippel-Lindau DiseaseNCT03401788
- May 5, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06428396
TargetBeta
“Endothelial PAS domain-containing protein 1 inhibitor”ChEMBL 37, by rule
Other programs on EPAS1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| casdatifanrule | Arcus Biosciences | phase 3 | 9 |
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07700758Neoplasms · United States, Belgium, Denmark and more | 2 | Recruiting | Jan 2, 2034 | 15 |
| NCT07405164von Hippel-Lindau Disease · United States, Australia, Belgium and more | 3 | Recruiting | Apr 22, 2034 | 450 |
| NCT07121959Healthy · United States | 1 | Completed | Sep 13, 2025 | 14 |
| NCT06903715Healthy · United States | 1 | Completed | May 8, 2025 | 14 |
| NCT06428396Breast Neoplasms · United States, Argentina, Canada and more | 2 | Active, not recruiting | May 5, 2027 | 120 |
| NCT05899049Carcinoma, Renal Cell · China | 3 | Active, not recruiting | Feb 4, 2026 | 251 |
| NCT05239728Carcinoma, Renal Cell · United States, Australia, Brazil and more | 3 | Active, not recruiting | Oct 28, 2026 | 1,800 |
| NCT05030506Carcinoma, Renal Cell · China | 1 | Active, not recruiting | Jun 30, 2027 | 45 |
| NCT04995484Moderate Hepatic Impairment · United States | 1 | Completed | Dec 25, 2023 | 17 |
| NCT04994522Kidney Failure, Chronic · United States | 1 | Completed | Apr 1, 2024 | 14 |
| NCT04976634Neoplasms · United States, Australia, Belgium and more | 2 | Active, not recruiting | Mar 22, 2027 | 730 |
| NCT04924075Pheochromocytoma · United States, Australia, Canada and more | 2 | Recruiting | Nov 18, 2032 | 355 |
| NCT04846920Carcinoma, Renal Cell · United States | 1 | Completed | Apr 11, 2026 | 29 |
| NCT04736706Carcinoma, Renal Cell · United States, Australia, Brazil and more | 3 | Active, not recruiting | Feb 4, 2026 | 1,688 |
| NCT04626518Carcinoma, Renal Cell · United States, Australia, Canada and more | 2 | Completed | Jul 23, 2026 | 263 |
| NCT04626479Carcinoma, Renal Cell · United States, Australia, Canada and more | 2 | Completed | Aug 10, 2026 | 393 |
| NCT04586231Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 2, 2026 | 747 |
| NCT04489771Carcinoma, Renal Cell · United States, Australia, Belgium and more | 2 | Completed | Feb 10, 2023 | 154 |
| NCT04195750Carcinoma, Renal Cell · United States, Brazil, Canada and more | 3 | Active, not recruiting | Apr 15, 2024 | 755 |
| NCT03634540Carcinoma, Renal Cell · United States | 2 | Active, not recruiting | Feb 26, 2027 | 118 |
| NCT03445169Healthy · United States | 1 | Completed | May 26, 2018 | 16 |
| NCT03401788von Hippel-Lindau Disease · United States, Denmark, France and more | 2 | Active, not recruiting | Apr 29, 2027 | 50 |
| NCT02974738Carcinoma, Renal Cell | 1 | Active, not recruiting | Jan 12, 2018 | 120 |
| NCT02861573Metastatic Castration-Resistant Prostate Cancer | 2 | Active, not recruiting | Oct 22, 2027 | 1,200 |
How it is read
Names in the registry
- “Belzutifan”, 23 entries
- “Belzutifan 120mg”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 12 studies
- Neoplasms, 2 studies
- von Hippel-Lindau Disease, 2 studies
- Pheochromocytoma, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.